Document is current
Any future updates will be listed below
-
Authors
Curtin, Nicola J.
Szabo, Csaba https://orcid.org/0000-0003-3110-4235
- License Information
-
More Information
Article History
Accepted: 30 June 2020
First Online: 3 September 2020
Competing interests
: C.S. has no conflicts of interest to declare. N.C. has served on the scientific advisory boards of various companies making PARP inhibitors (AbbVie, BioMarin, Eisai and Tesaro) and other DNA damage response inhibitors (Sierra). She has received royalty payments from the commercial development of Rubraca, which have been used to fund her group’s research and to establish the Curtin PARP (Passionate About Realizing your Potential) Fund at the Community Foundation (UK). Her PARP-related work has been supported by funding from Agouron Pharmaceuticals, Pfizer, Clovis, BioMarin and BiPar Sciences.
